182 related articles for article (PubMed ID: 33134385)
1. lncRNA CASC2 Enhances
Tao L; Tian P; Yang L; Guo X
Biomed Res Int; 2020; 2020():7183629. PubMed ID: 33134385
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
[TBL] [Abstract][Full Text] [Related]
3. LncRNA CASC2 expression is down- regulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway.
Zhou T; Zhong M; Zhang S; Wang Z; Xie R; Xiong C; Lv Y; Chen W; Yu J
Cancer Biomark; 2018; 23(2):185-191. PubMed ID: 30175973
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis.
Wang J; Jia J; Zhou L
Neoplasma; 2020 Nov; 67(6):1279-1292. PubMed ID: 32787433
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway.
Liu C; Feng Z; Chen T; Lv J; Liu P; Jia L; Zhu J; Chen F; Yang C; Deng Z
Cell Cycle; 2019 Jan; 18(2):167-203. PubMed ID: 30596336
[TBL] [Abstract][Full Text] [Related]
6. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA LINC00520 accelerates progression of papillary thyroid carcinoma by serving as a competing endogenous RNA of microRNA-577 to increase Sphk2 expression.
Sun Y; Shi T; Ma Y; Qin H; Li K
Cell Cycle; 2020 Apr; 19(7):787-800. PubMed ID: 32075502
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
Chen Y; Li Y; Gao H
Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
[TBL] [Abstract][Full Text] [Related]
9. METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer.
Zhang X; Li D; Jia C; Cai H; Lv Z; Wu B
Cell Death Dis; 2021 Jun; 12(6):617. PubMed ID: 34131102
[TBL] [Abstract][Full Text] [Related]
10. Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212.
Wang R; Zhao L; Ji L; Bai L; Wen Q
Biomed Pharmacother; 2019 Oct; 118():109298. PubMed ID: 31404776
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma.
Liu F; Yin R; Chen X; Chen W; Qian Y; Zhao Y; Jiang Y; Ma D; Hu T; Yu T; Zhu Y; Zhang Y
Biomed Pharmacother; 2019 Jun; 114():108605. PubMed ID: 30904818
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression.
Zhang H; Cai Y; Zheng L; Zhang Z; Lin X; Jiang N
J Cell Physiol; 2018 Oct; 233(10):6638-6648. PubMed ID: 29319165
[TBL] [Abstract][Full Text] [Related]
13. The lncRNA SNHG3 accelerates papillary thyroid carcinoma progression via the miR-214-3p/PSMD10 axis.
Sui G; Zhang B; Fei D; Wang H; Guo F; Luo Q
J Cell Physiol; 2020 Oct; 235(10):6615-6624. PubMed ID: 32048306
[TBL] [Abstract][Full Text] [Related]
14. LncRNA MEG3 enhances
Liu Y; Yue P; Zhou T; Zhang F; Wang H; Chen X
Biomed Pharmacother; 2018 Sep; 105():1232-1239. PubMed ID: 30021359
[TBL] [Abstract][Full Text] [Related]
15. miR-744-5p mediates lncRNA HOTTIP to regulate the proliferation and apoptosis of papillary thyroid carcinoma cells.
Yuan Q; Fan Y; Liu Z; Wang X; Jia M; Geng Z; Zheng J; Lu X
Exp Cell Res; 2020 Jul; 392(1):112024. PubMed ID: 32335029
[TBL] [Abstract][Full Text] [Related]
16. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637.
Yuan Q; Liu Y; Fan Y; Liu Z; Wang X; Jia M; Geng Z; Zhang J; Lu X
Int J Biochem Cell Biol; 2018 May; 98():1-9. PubMed ID: 29474928
[TBL] [Abstract][Full Text] [Related]
17. CASC2 inhibits the growth, migration, and invasion of thyroid cancer cells through sponging miR-18a-5p/FIH1 axis.
Liu QY; Gao LY; Xu L; Zhang XL; Zhang LJ; Gong XL; Luo SB; Zhao R; Cheng RC
Kaohsiung J Med Sci; 2021 Apr; 37(4):268-275. PubMed ID: 33336500
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma.
Feng Z; Chen R; Huang N; Luo C
Life Sci; 2020 Mar; 244():117298. PubMed ID: 31953163
[TBL] [Abstract][Full Text] [Related]
19. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a/PLXNC1 axis in melanoma.
Wang Z; Wang X; Zhou H; Dan X; Jiang L; Wu Y
Acta Biochim Biophys Sin (Shanghai); 2018 Mar; 50(3):263-272. PubMed ID: 29514220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]